← Back to Search

Fluoroquinolone Antibiotic

Gatifloxacin 0.5% Eye Drops for Pink Eye

Phase 3
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Clinically diagnosed with bacterial conjunctivitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 6
Awards & highlights
All Individual Drugs Already Approved
Pivotal Trial

Summary

The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis

Eligible Conditions
  • Pink Eye

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6
Secondary study objectives
Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6
Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6
Percentage of Patients With Microbiological Cure at Day 6

Side effects data

From 2008 Phase 3 trial • 578 Patients • NCT00509873
5%
Conjunctivitis bacterial
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo Eye Drops
Gatifloxacin 0.5% Eye Drops

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Gatifloxacin 0.5% Eye DropsExperimental Treatment1 Intervention
Gatifloxacin 0.5% Eye Drops
Group II: Placebo Eye DropsPlacebo Group1 Intervention
Placebo Eye Drops
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gatifloxacin
FDA approved

Find a Location

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
276,107 Total Patients Enrolled
Medical DirectorStudy DirectorAllergan
2,895 Previous Clinical Trials
8,088,190 Total Patients Enrolled
~32 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top